Introduction

Handok Continues the Challenge of
Developing New Drugs at a Global Level.
Handok’s R&D
  • Development of Global Innovative
    New Drugs and Biopharmaceuticals     Innovative drug development with global competitiveness in the fields of cancer, diabetes, and rare diseases.
  • IMD (Incrementally Modified Drug)/
    Fixed-Dose Combination Drug Development     Development of combination drugs using Dual Release Micro-coating (DRM) technology for sustained and immediate release formulations (Tenelia M sustained-release tablets, Amaryl MEX sustained-release tablets ).
  • Innovative Patch
    Formulation Development     Development of various patch formulations utilizing Transdermal Drug Delivery System (TDDS) technology.
  • Subsidiary Innocuve,
    Discovery and Nurturing of
    Early-Stage Bio Healthcare Startups
 
Handok secures global competitiveness in
R&D capabilities based on an open innovation strategy.
  • Genexine Growth Hormone Deficiency in Adults/Pediatrics - Development and commercialization rights for Korea.
  • Rezolute Intravenous monoclonal antibody for Congenital Hyperinsulinism / Oral Plasma Kallikrein Inhibitor for Diabetic Macular Edema - Development and commercialization rights for Korea.
  • ABL Bio Domestic market development and commercialization rights for bile duct cancer treatments, ongoing global Phase 2/3 trials with Compass Therapeutics, domestic market development and commercialization rights for dual-antibody cancer treatments
  • CMG Pharma Joint research on targeted cancer treatments (technology transfer to Singapore’s AUM Biosciences)
  • SPARK Biopharma Domestic market development and commercialization rights for melanoma/bile duct cancer/glioblastoma cancer treatments
  • SCM Lifescience Domestic market development and commercialization rights for stem cell treatments for severe atopic dermatitis
 
 
Introduction to Handok
Future Complex

168 Magok Central Road, Gangseo-gu, Seoul (Zip)07789
Approximately 21,837m²
(8 floors above ground, 3 floors underground)

In 2022, Handok completed the Handok Future Complex and strengthened its R&D capabilities by integrating the Product Development Research Institute and the New Drug Development Research Institute.
  • Optimal space for pharmaceutical research
  • High-ceilinged and open research laboratory space for creative thinking
  • Meeting lounges, Open Lab, cafeteria, etc. for free communication and collaboration
  • Walking paths, libraries, atriums of various concepts, etc. for researchers’ rest
  • Fitness center, mother’s room, independent rest areas, etc. for Work & Life Balance
맨위로